MINNEAPOLIS, April 05, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (the “Company”) (TSX-V:DMA) (OTCQB:DMCAF) is pleased to announce the appointment of Mr. Scott Kellen as Chief Financial Officer and Corporate Secretary.
“We are extremenly pleased to welcome Scott to DiaMedica’s executive team,” notes Mr. Rick Pauls, President and CEO. “Scott brings a strong background in financial strategy and reporting, previously working in various roles with several publicly traded healthcare companies, and his deep understanding of the financial needs of development stage biotechs will prove invaluable to us as we execute on our clinical development plans and next phases of growth.”
Mr. Kellen is a highly qualified senior executive with corporate board experience. He has held positions as Chief Operating Officer and Chief Financial Officer within publicly traded healthcare companies, most recently as CFO for Sun Bio Pharma. In addition to the positions he has played, Mr. Kellen has significant experience with capital formation, public company reporting and corporate governance.
Mr. Kellen has held a Certified Public Accountant certificate, and graduated summa cum laude from the University of South Dakota with a Bachelor of Science in Business Administration. He stated, "It is a tremendous opportunity to become a part of the DiaMedica executive team at such an exciting time and stage of development." Mr. Kellen further commented, "I'm eager to be joining the team as we continue to refine the corporate strategy and advance the DM 199 pipeline."
The company today also announced the resignation of David Gurvey as VP finance. On behalf of the Board of DiaMedica, the Company would like to extend its warmest gratitude to David Gurvey for his valuable contributions to DiaMedica and wishes him the best in his future endeavors.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica’s shares are listed on the TSX Venture Exchange under the trading symbol “DMA” and on the OTCQB under the trading symbol “DMCAF”. For more information, please visit www.diamedica.com. Follow us on social media – Twitter, LinkedIn.
For further information, please contact:
Paul Papi
Vice President of Business Development
DiaMedica Therapeutics Inc.
Two Carlson Parkway, Suite 260
Minneapolis, MN
Phone: (617) 899-5941
info@diamedica.com
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.